SI-BONE, Inc.

SI-BONE, Inc.

SIBNNYSE / NASDAQHealthcareSmall cap

$23.73-$0.02 (-0.1%)

Last close · Data as of Nov 20, 2026

Market cap
$659.9M
Revenue
$200.9M
Net margin
-9.4%
ROCE
-7.6%

+27.0% over the last year

SI-BONE, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+15.5%
3M
+21.8%
6M
+60.1%
1Y
+27.0%
5Y
+11.7%

52-week range

Day change -$0.02 (-0.1%) from $24 to $24 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in SIBN, bought on each weekday since 2021.

News & filings

What SI-BONE filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 18.9 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 8.55 times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.

Read moreShow less

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Sector
Healthcare
Shares outstanding
43.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$659.9M
P/B
3.7x
EV / Sales
2.7x
P/S
3.3x
52-week high
$25.60
52-week low
$11.61

Profitability

Operating margin
-11.1%
Net margin
-9.4%
EBITDA margin
-5.2%
ROE
-10.6%
ROCE
-7.6%
ROIC
-7.5%
ROA
-7.9%
Asset turnover
0.84

Growth

Revenue
$200.9M
Revenue growth, 1Y
20.2%
Revenue CAGR, 3Y
23.6%
Net profit growth, 1Y
-38.8%
Free cash flow
-$9.1M

Solvency

Current ratio
8.55
Debt / Equity
0.21
Debt / Assets
0.15
CFO / Net profit
0.04
Cash / Market cap
22.4%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$200.9M
Cost of revenue$41.0M
Gross profit$159.9M
Operating expenses$182.2M
Research and development$17.4M
Selling, general and administrative$164.8M
Operating income-$22.3M
Interest and other$3.4M
Pretax income-$18.9M
Tax and other$0.00
Net income-$18.9M

Revenue and net profit

Revenue grew 20.2% in FY2025; net profit is the dashed line.

SI-BONE, Inc. revenue and net profit by fiscal year
SI-BONE, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$106.4M-$61.3M
FY2023$138.9M-$43.3M
FY2024$167.2M-$30.9M
FY2025$200.9M-$18.9M

Cash flows

FY2025: -$675.0k from operations, -$9.1M free after investment (dashed).

SI-BONE, Inc. operating and free cash flow by fiscal year
SI-BONE, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$41.7M-$51.2M
FY2023-$18.7M-$26.5M
FY2024-$12.4M-$22.9M
FY2025-$675.0k-$9.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$200.9M+20.2%1Y
EBITDA
-$10.5M
Net profit
-$18.9M
Cash from operations
-$675.0k
Free cash flow
-$9.1M
Revenue CAGR, 3Y
23.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$200.9M-$10.5M-$18.9M-$9.1M-10.6%+20.2%-38.8%

Monthly returns

Month-by-month returns of SIBN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$238.6M
Liabilities$61.0M
Equity$177.5M
Paid-in capital$627.0M
Retained earnings-$450.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; SIBN highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. SI-BONE, Inc. (this company)2.7x

Not shown (no positive earnings and no EV / Sales): Candel Therapeutics, Inc., Design Therapeutics, Inc., First Tracks Biotherapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
SI-BONE, Inc.SIBNthis company$659.9M—3.7x-10.6%—
Candel Therapeutics, Inc.CADL$679.2M-17.8x13.1x-73.5%-17.3x
Design Therapeutics, Inc.DSGN$672.0M-9.6x3.2x-32.8%-8.3x
CorMedix Inc.CRMD$670.0M4.1x1.7x40.0%4.0x
Zevra Therapeutics, Inc.ZVRA$660.3M7.9x4.3x53.8%6.7x
Aclaris Therapeutics, Inc.ACRS$657.8M-10.1x6.4x-63.0%—
Castle Biosciences, Inc.CSTL$655.1M-27.1x1.4x-5.1%50.7x
First Tracks Biotherapeutics, Inc.TRAX$635.0M-3.9x1.6x-41.8%-3.0x
Prime Medicine, Inc.PRME$626.7M-3.1x5.2x-166.4%-3.4x
Peer median—-6.8x3.7x-37.3%-3.0x

Year-to-date ROI

SIBN since 1 January, against earlier years.

Historical volatility

SIBN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

SI-BONE, Inc. operating margin by fiscal year
SI-BONE, Inc. operating margin by fiscal year
DateOperating margin
FY2022-56.0%
FY2023-33.8%
FY2024-21.1%
FY2025-11.1%
LineFY2025
Cost of revenueCost Of Revenue$41.0M
Gross profitGross Profit$159.9M
Operating expensesOperating Expense$182.2M
Research and developmentResearch And Development$17.4M
Total expensesTotal Expenses$223.3M
Pretax incomePretax Income-$18.9M

Learn while you research

Academy chapters picked for SI-BONE, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing20% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →